Free Trial
NASDAQ:BIAF

bioAffinity Technologies Q1 2025 Earnings Report

bioAffinity Technologies logo
$0.27 -0.03 (-10.82%)
As of 01:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

bioAffinity Technologies EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.16
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
$1.85 million
Expected Revenue
$2.11 million
Beat/Miss
Missed by -$255.00 thousand
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
9:00AM ET

Upcoming Earnings

bioAffinity Technologies' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Wednesday, August 13, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

bioAffinity Technologies Earnings Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

View bioAffinity Technologies Profile

More Earnings Resources from MarketBeat